Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryysy, L.
Right arrow Articles by Yki-Jarvinen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryysy, L.
Right arrow Articles by Yki-Jarvinen, H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 49, Issue 5 749-758, Copyright © 2000 by American Diabetes Association

ARTICLES

Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients

L Ryysy, AM Hakkinen, T Goto, S Vehkavaara, J Westerbacka, J Halavaara and H Yki-Jarvinen
Department of Medicine, University of Helsinki, Finland.

To determine causes of interindividual variation in insulin requirements, we recruited 20 type 2 diabetic patients with stable glucose control and insulin doses for >1 year on combination therapy with bedtime NPH insulin and metformin. Insulin absorption (increase in free and total insulin over 8 h after a subcutaneous dose of regular insulin) and actions of intravenous (6-h 0.3 mU x kg(-1) x min(-1) euglycemic insulin clamp combined with [3-3H]glucose) and subcutaneous (glucose infusion rate required to maintain isoglycemia and suppression of free fatty acids [FFAs]) insulin, liver fat content (proton spectroscopy), visceral fat (magnetic resonance imaging), weight, and body composition were determined. We found the following variation in parameters: insulin dose range 10-176 U (mean 42 U, fold variation 17.6x) or 0.13-1.39 U/kg (0.44 U/kg, 10.7x), absorbed insulin 10.6x, action of subcutaneous insulin to suppress FFAs 7.5 x and to stimulate glucose metabolism (M value) 11.5x, body weight 67-127 kg (91 kg, 1.9x), liver fat 2-28% (12%, 14x), and visceral fat 179-2,053 ml (1,114 ml, 11.5x). The amount of insulin absorbed, measured as either free or total insulin, was significantly correlated with its ability to suppress FFAs and stimulate glucose metabolism but not with the insulin dose per se. The actions of absorbed insulin were, on the other hand, significantly correlated with the daily insulin dose (r = 0.70 for action on FFAs, P < 0.001, and r = -0.61 for M value, P < 0.005). Actions of subcutaneous and intravenous insulin to suppress FFAs were significantly correlated (r = 0.82, P < 0.001, R2 = 67%). Of the measures of adiposity, the percent hepatic fat was the parameter best correlated with the daily insulin dose (r = 0.76, P < 0.001). The percent hepatic fat was also significantly correlated with the ability of intravenous insulin to suppress endogenous glucose production (r = 0.72, P < 0.005). We conclude that the major reason for interindividual variation in insulin requirements in type 2 diabetes is the variation in insulin action. Variation in hepatic fat content may influence insulin requirements via an effect on the sensitivity of endogenous glucose production to insulin.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
B. Ravikumar, J. Gerrard, C. Dalla Man, M. J. Firbank, A. Lane, P. T. English, C. Cobelli, and R. Taylor
Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content
Diabetes, September 1, 2008; 57(9): 2288 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Shibata, Y. Kihara, M. Taguchi, M. Tashiro, and M. Otsuki
Nonalcoholic Fatty Liver Disease Is a Risk Factor for Type 2 Diabetes in Middle-Aged Japanese Men
Diabetes Care, November 1, 2007; 30(11): 2940 - 2944.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Kotronen, J. Westerbacka, R. Bergholm, K. H. Pietilainen, and H. Yki-Jarvinen
Liver Fat in the Metabolic Syndrome
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3490 - 3497.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. W. Herling, M. Gossel, G. Haschke, S. Stengelin, J. Kuhlmann, G. Muller, D. Schmoll, and W. Kramer
CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E826 - E832.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Matikainen, S. Manttari, J. Westerbacka, S. Vehkavaara, N. Lundbom, H. Yki-Jarvinen, and M.-R. Taskinen
Postprandial Lipemia Associates with Liver Fat Content
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3052 - 3059.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Sato, Y. Tamura, H. Watada, N. Kumashiro, Y. Igarashi, H. Uchino, T. Maehara, S. Kyogoku, S. Sunayama, H. Sato, et al.
Effects of Diet-Induced Moderate Weight Reduction on Intrahepatic and Intramyocellular Triglycerides and Glucose Metabolism in Obese Subjects
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3326 - 3329.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. Azuma, L. K. Heilbronn, J. B. Albu, S. R. Smith, E. Ravussin, D. E. Kelley, and and the Look AHEAD Adipose Research Group
Adipose tissue distribution in relation to insulin resistance in type 2 diabetes mellitus
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E435 - E442.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Y. Chang, S. Ryu, E. Sung, and Y. Jang
Higher Concentrations of Alanine Aminotransferase within the Reference Interval Predict Nonalcoholic Fatty Liver Disease
Clin. Chem., April 1, 2007; 53(4): 686 - 692.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. J. Prior, L. J. Joseph, J. Brandauer, L. I. Katzel, J. M. Hagberg, and A. S. Ryan
Reduction in Midthigh Low-Density Muscle with Aerobic Exercise Training and Weight Loss Impacts Glucose Tolerance in Older Men
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 880 - 886.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. Juurinen, M. Tiikkainen, A.-M. Hakkinen, A. Hakkarainen, and H. Yki-Jarvinen
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E829 - E835.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. G.S. Toledo, A. D. Sniderman, and D. E. Kelley
Influence of Hepatic Steatosis (Fatty Liver) on Severity and Composition of Dyslipidemia in Type 2 Diabetes
Diabetes Care, August 1, 2006; 29(8): 1845 - 1850.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. H. Pietilainen, K. Kannisto, E. Korsheninnikova, A. Rissanen, J. Kaprio, E. Ehrenborg, A. Hamsten, and H. Yki-Jarvinen
Acquired Obesity Increases CD68 and Tumor Necrosis Factor-{alpha} and Decreases Adiponectin Gene Expression in Adipose Tissue: A Study in Monozygotic Twins
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2776 - 2781.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. J. Raubenheimer, M. J. Nyirenda, and B. R. Walker
A Choline-Deficient Diet Exacerbates Fatty Liver but Attenuates Insulin Resistance and Glucose Intolerance in Mice Fed a High-Fat Diet.
Diabetes, July 1, 2006; 55(7): 2015 - 2020.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. E. Larson-Meyer, L. K. Heilbronn, L. M. Redman, B. R. Newcomer, M. I. Frisard, S. Anton, S. R. Smith, A. Alfonso, E. Ravussin, and the Pennington CALERIE Team
Effect of Calorie Restriction With or Without Exercise on Insulin Sensitivity, {beta}-Cell Function, Fat Cell Size, and Ectopic Lipid in Overweight Subjects.
Diabetes Care, June 1, 2006; 29(6): 1337 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
C.-W. Chen and H.-H. Cheng
A Rice Bran Oil Diet Increases LDL-Receptor and HMG-CoA Reductase mRNA Expressions and Insulin Sensitivity in Rats with Streptozotocin/Nicotinamide-Induced Type 2 Diabetes
J. Nutr., June 1, 2006; 136(6): 1472 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Beha, H.-P. Juretschke, J. Kuhlmann, C. Neumann-Haefelin, U. Belz, M. Gerl, W. Kramer, M. Roden, and A. W. Herling
Muscle type-specific fatty acid metabolism in insulin resistance: an integrated in vivo study in Zucker diabetic fatty rats
Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E989 - E997.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Deng, S. Shan, P.-P. Li, Z.-F. Shen, X.-P. Lu, J. Cheng, and Z.-Q. Ning
Peroxisome Proliferator-Activated Receptor-{gamma} Transcriptionally Up-Regulates Hormone-Sensitive Lipase via the Involvement of Specificity Protein-1
Endocrinology, February 1, 2006; 147(2): 875 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. S.W. Taylor, S. R.P. Williams, R. Rhys, P. James, and M. P. Frenneaux
Conjugated Linoleic Acid Impairs Endothelial Function
Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 307 - 312.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
P. E. Carey, J. Gerrard, G. W. Cline, C. Dalla Man, P. T. English, M. J. Firbank, C. Cobelli, and R. Taylor
Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production
Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E941 - E947.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. S. Reingold, J. M. McGavock, S. Kaka, T. Tillery, R. G. Victor, and L. S. Szczepaniak
Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method
Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E935 - E939.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Tamura, Y. Tanaka, F. Sato, J. B. Choi, H. Watada, M. Niwa, J. Kinoshita, A. Ooka, N. Kumashiro, Y. Igarashi, et al.
Effects of Diet and Exercise on Muscle and Liver Intracellular Lipid Contents and Insulin Sensitivity in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3191 - 3196.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. M. Watts, V. P. Manchem, T. A. Leedom, A. L. Rivard, R. A. McKay, D. Bao, T. Neroladakis, B. P. Monia, D. M. Bodenmiller, J. X.-C. Cao, et al.
Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism
Diabetes, June 1, 2005; 54(6): 1846 - 1853.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Westerbacka, K. Lammi, A.-M. Hakkinen, A. Rissanen, I. Salminen, A. Aro, and H. Yki-Jarvinen
Dietary Fat Content Modifies Liver Fat in Overweight Nondiabetic Subjects
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2804 - 2809.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. H. Pietilainen, A. Rissanen, J. Kaprio, S. Makimattila, A.-M. Hakkinen, J. Westerbacka, J. Sutinen, S. Vehkavaara, and H. Yki-Jarvinen
Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins
Am J Physiol Endocrinol Metab, April 1, 2005; 288(4): E768 - E774.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. Ravikumar, P. E. Carey, J. E. M. Snaar, D. K. Deelchand, D. B. Cook, R. D. G. Neely, P. T. English, M. J. Firbank, P. G. Morris, and R. Taylor
Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes
Am J Physiol Endocrinol Metab, April 1, 2005; 288(4): E789 - E797.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Kabir, K. J. Catalano, S. Ananthnarayan, S. P. Kim, G. W. Van Citters, M. K. Dea, and R. N. Bergman
Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance
Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E454 - E461.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S. B Haugaard, O. Andersen, F. Dela, J. J. Holst, H. Storgaard, M. Fenger, J. Iversen, and S. Madsbad
Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic {beta}-cells
Eur. J. Endocrinol., January 1, 2005; 152(1): 103 - 112.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Krssak, A. Brehm, E. Bernroider, C. Anderwald, P. Nowotny, C. D. Man, C. Cobelli, G. W. Cline, G. I. Shulman, W. Waldhausl, et al.
Alterations in Postprandial Hepatic Glycogen Metabolism in Type 2 Diabetes
Diabetes, December 1, 2004; 53(12): 3048 - 3056.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Z. Strowski, Z. Li, D. Szalkowski, X. Shen, X.-M. Guan, S. Juttner, D. E. Moller, and B. B. Zhang
Small-Molecule Insulin Mimetic Reduces Hyperglycemia and Obesity in a Nongenetic Mouse Model of Type 2 Diabetes
Endocrinology, November 1, 2004; 145(11): 5259 - 5268.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. T. Schroeder, L. Zheng, M. D. Ong, C. Martinez, C. Flores, Y. Stewart, C. Azen, and F. R. Sattler
Effects of Androgen Therapy on Adipose Tissue and Metabolism in Older Men
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4863 - 4872.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Yki-Jarvinen
Thiazolidinediones
N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. G. Cree, B. R. Newcomer, C. S. Katsanos, M. Sheffield-Moore, D. Chinkes, A. Aarsland, R. Urban, and R. R. Wolfe
Intramuscular and Liver Triglycerides Are Increased in the Elderly
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3864 - 3871.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Tiikkainen, A.-M. Hakkinen, E. Korsheninnikova, T. Nyman, S. Makimattila, and H. Yki-Jarvinen
Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes
Diabetes, August 1, 2004; 53(8): 2169 - 2176.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. D. Hegarty, S. M. Furler, N. D. Oakes, E. W. Kraegen, and G. J. Cooney
Peroxisome Proliferator-Activated Receptor (PPAR) Activation Induces Tissue-Specific Effects on Fatty Acid Uptake and Metabolism in Vivo--A Study Using the Novel PPAR{alpha}/{gamma} Agonist Tesaglitazar
Endocrinology, July 1, 2004; 145(7): 3158 - 3164.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. K. Heilbronn, J. Rood, L. Janderova, J. B. Albu, D. E. Kelley, E. Ravussin, and S. R. Smith
Relationship between Serum Resistin Concentrations and Insulin Resistance in Nonobese, Obese, and Obese Diabetic Subjects
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1844 - 1848.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Neumann-Haefelin, A. Beha, J. Kuhlmann, U. Belz, M. Gerl, M. Quint, G. Biemer-Daub, M. Broenstrup, M. Stein, E. Kleinschmidt, et al.
Muscle-Type Specific Intramyocellular and Hepatic Lipid Metabolism During Starvation in Wistar Rats
Diabetes, March 1, 2004; 53(3): 528 - 534.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Bays, L. Mandarino, and R. A. DeFronzo
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Alam, M. Stolinski, C. Pentecost, M. A. Boroujerdi, R. H. Jones, P. H. Sonksen, and A. M. Umpleby
The Effect of a Six-Month Exercise Program on Very Low-Density Lipoprotein Apolipoprotein B Secretion in Type 2 Diabetes
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 688 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. Tiikkainen, R. Bergholm, A. Rissanen, A. Aro, I. Salminen, M. Tamminen, K. Teramo, and H. Yki-Jarvinen
Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women
Am. J. Clinical Nutrition, January 1, 2004; 79(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Bajaj, S. Suraamornkul, P. Piper, L. J. Hardies, L. Glass, E. Cersosimo, T. Pratipanawatr, Y. Miyazaki, and R. A. DeFronzo
Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 200 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. E. Kelley, L. H. Kuller, T. M. McKolanis, P. Harper, J. Mancino, and S. Kalhan
Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 33 - 40.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Westerbacka, H. Yki-Jarvinen, S. Vehkavaara, A.-M. Hakkinen, R. Andrew, D. J. Wake, J. R. Seckl, and B. R. Walker
Body Fat Distribution and Cortisol Metabolism in Healthy Men: Enhanced 5{beta}-Reductase and Lower Cortisol/Cortisone Metabolite Ratios in Men with Fatty Liver
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4924 - 4931.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. E. Kelley, T. M. McKolanis, R. A. F. Hegazi, L. H. Kuller, and S. C. Kalhan
Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E906 - E916.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. P. Kim, M. Ellmerer, G. W. Van Citters, and R. N. Bergman
Primacy of Hepatic Insulin Resistance in the Development of the Metabolic Syndrome Induced by an Isocaloric Moderate-Fat Diet in the Dog
Diabetes, October 1, 2003; 52(10): 2453 - 2460.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. R. Smith, F. Bai, C. Charbonneau, L. Janderova, and G. Argyropoulos
A Promoter Genotype and Oxidative Stress Potentially Link Resistin to Human Insulin Resistance
Diabetes, July 1, 2003; 52(7): 1611 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Kim, M. Haluzik, Z. Asghar, D. Yau, J. W. Joseph, A. M. Fernandez, M. L. Reitman, S. Yakar, B. Stannard, L. Heron-Milhavet, et al.
Peroxisome Proliferator-Activated Receptor-{alpha} Agonist Treatment in a Transgenic Model of Type 2 Diabetes Reverses the Lipotoxic State and Improves Glucose Homeostasis
Diabetes, July 1, 2003; 52(7): 1770 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Bajaj, S. Suraamornkul, T. Pratipanawatr, L. J. Hardies, W. Pratipanawatr, L. Glass, E. Cersosimo, Y. Miyazaki, and R. A. DeFronzo
Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes
Diabetes, June 1, 2003; 52(6): 1364 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
H. Yki-Jarvinen, J. Sutinen, A. Silveira, E. Korsheninnikova, R. M. Fisher, K. Kannisto, E. Ehrenborg, P. Eriksson, and A. Hamsten
Regulation of Plasma PAI-1 Concentrations in HAART-Associated Lipodystrophy During Rosiglitazone Therapy
Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 688 - 694.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Tiikkainen, R. Bergholm, S. Vehkavaara, A. Rissanen, A.-M. Hakkinen, M. Tamminen, K. Teramo, and H. Yki-Jarvinen
Effects of Identical Weight Loss on Body Composition and Features of Insulin Resistance in Obese Women With High and Low Liver Fat Content
Diabetes, March 1, 2003; 52(3): 701 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
V. Simha, L. S. Szczepaniak, A. J. Wagner, A. M. DePaoli, and A. Garg
Effect of Leptin Replacement on Intrahepatic and Intramyocellular Lipid Content in Patients With Generalized Lipodystrophy
Diabetes Care, January 1, 2003; 26(1): 30 - 35.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Anderwald, E. Bernroider, M. Krssak, H. Stingl, A. Brehm, M. G. Bischof, P. Nowotny, M. Roden, and W. Waldhausl
Effects of Insulin Treatment in Type 2 Diabetic Patients on Intracellular Lipid Content in Liver and Skeletal Muscle
Diabetes, October 1, 2002; 51(10): 3025 - 3032.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Seppala-Lindroos, S. Vehkavaara, A.-M. Hakkinen, T. Goto, J. Westerbacka, A. Sovijarvi, J. Halavaara, and H. Yki-Jarvinen
Fat Accumulation in the Liver Is Associated with Defects in Insulin Suppression of Glucose Production and Serum Free Fatty Acids Independent of Obesity in Normal Men
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3023 - 3028.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. E. Kelley, G. A. Bray, F. X. Pi-Sunyer, S. Klein, J. Hill, J. Miles, and P. Hollander
Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes: A 1-year randomized controlled trial
Diabetes Care, June 1, 2002; 25(6): 1033 - 1041.
[Abstract] [Full Text] [PDF]